-
- 2023.8.22
Award Notice: “The Japan Start-up Encouragement Prize”
Ai-BrainScience Inc. (Office: Osaka, CEO; Kentaro Takamura, Ph.D., “the company” hereinafter) announce that the company received from the Japan Cabinet Office “The Japan Medical Research and Development Start-up Encouragement Prize” for developing the eye-tracking-based cognitive assessment as Medical Dx.
The Japan Medical Research and Development Grand Prize has been established to recognize achievements in promoting research and development in the medical field, thereby deepening public interest and understanding, and incentivizing researchers. The Award was launched in 2009 and is now in its 6th year. This year, a new startup category has been added to recognize startup companies with promising prospects in the medical R&D.
Prize Content
Prize 6th Japan Medical Research and Development Grand Prize Startup Encouragement Prize Title 【Medical Dx】Development of Eye-Tracking based Cognitive Assessment Application Achievement The company develop the cognitive assessment application using patients ‘gaze data as “Software as Medical Device” to deal with the social challenges of dementia. The technology will help identify more patients with cognitive decline at earlier stage and accelerate further prevention. Also, the technology will reduce both the patients’ mental stress and the capacity of medical staff. Overview ・There is a clinical bottleneck in dementia diagnosis, because the conventional questionnaire-based cognitive assessment has several problems including “inflicting mental stress on patients”, “lengthy time over 15 minutes”, and “score vary depend on physicians”. ・The eye-tracking based technology will provide objective cognitive assessment using patients’ gaze data within 3 minutes. In addition, the technology is designed to cause much less mental stress on patients because their answer is unknown during the assessment whether it is correct or wrong. Also, the assessment score will not vary because the technology is independent of physicians’ experience and skills.
・The technology can take advantages of language-independence so that the software can be used globally.
The company will continue to develop products that satisfy unmet needs in the medical field.
＜Cite＞
The Japan Medical Research and Development Grand Prize：
https://www.kantei.go.jp/jp/singi/kenkouiryou/pdf/kaihatsu_taishou_6.pdf